Modern Rheumatology最新文献_第10页

Correction to: Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study. 更正：阿伐潘对日本抗中性粒细胞胞浆抗体相关性血管炎患者的疗效和安全性：一项 3 期随机研究的子分析。

IF 2.2 4区医学

Modern Rheumatology Pub Date : 2024-05-27 DOI: 10.1093/mr/roae045

引用次数: 0

Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: a systematic review. 肿瘤坏死因子抑制剂治疗全身性幼年特发性关节炎的有效性和安全性：系统性综述。

IF 2.2 4区医学

Modern Rheumatology Pub Date : 2024-05-25 DOI: 10.1093/mr/roae050

Takashi Ishikawa, Kenichi Nishimura, Nami Okamoto, Keiji Akamine, Natsumi Inoue, Hitoshi Irabu, Kentaro Kato, Hiroshi Keino, Masayo Kojima, Hiroshi Kubo, Kazuichi Maruyama, Mao Mizuta, Kosuke Shabana, Masaki Shimizu, Yuko Sugita, Yukiko Takakuwa, Satoshi Takanashi, Hiroshi Takase, Hiroaki Umebayashi, Natsuka Umezawa, Shingo Yamanishi, Kazuko Yamazaki, Masato Yashiro, Takahiro Yasumi, Masaaki Mori

{"title":"Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: a systematic review.","authors":"Takashi Ishikawa, Kenichi Nishimura, Nami Okamoto, Keiji Akamine, Natsumi Inoue, Hitoshi Irabu, Kentaro Kato, Hiroshi Keino, Masayo Kojima, Hiroshi Kubo, Kazuichi Maruyama, Mao Mizuta, Kosuke Shabana, Masaki Shimizu, Yuko Sugita, Yukiko Takakuwa, Satoshi Takanashi, Hiroshi Takase, Hiroaki Umebayashi, Natsuka Umezawa, Shingo Yamanishi, Kazuko Yamazaki, Masato Yashiro, Takahiro Yasumi, Masaaki Mori","doi":"10.1093/mr/roae050","DOIUrl":"https://doi.org/10.1093/mr/roae050","url":null,"abstract":"Objectives: This systematic review assessed the efficacy and safety of tumor necrosis factor (TNF) inhibitors in patients with systemic juvenile idiopathic arthritis (JIA).Methods: Studies were searched using PubMed, Embase, Cochrane, Ichushi-Web, and clinical trial registries (from 2000 to 2021). The risk of bias was assessed using the Cochrane Risk of Bias version 2 for randomized controlled trials (RCTs) and the manual for development clinical practice guidelines by Minds, a project promoting evidence-based medicine in Japan, for observational studies.Results: One RCT and 22 observational studies were included. In the RCT on infliximab, the American College of Rheumatology pediatric (ACR Pedi) 30/50/70 responses at 14 weeks were 63.8%/50.0%/22.4%, with relative risks of 1.30 (95% confidence interval [CI]: 0.94-1.79)/1.48 (95% CI: 0.95-2.29)/1.89 (95% CI: 0.81-4.40), respectively. In the observational studies, ACR Pedi 30/50/70 responses for etanercept at 12 months were 76.7%/64.7%/46.4%, respectively. Infliximab treatment caused anaphylaxis in 17% and an infusion reaction in 23% of patients. The incidence of macrophage activation syndrome, serious infection and malignancy caused by TNF inhibitors was 0%-4%.Conclusions: Thus, although TNF inhibitors were relatively safe, they were unlikely to be preferentially administered in patients with systemic JIA because of their inadequate efficacy. Further studies, particularly well-designed RCTs, are necessary to confirm the efficacy and safety of TNF inhibitors for systemic JIA.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141097240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factor analysis of vertebral fractures requiring surgery in patients with ankylosing spondylitis. 强直性脊柱炎患者需要手术治疗的脊椎骨折的风险因素分析。

IF 2.2 4区医学

Modern Rheumatology Pub Date : 2024-05-25 DOI: 10.1093/mr/roae048

Kazuhiro Kai, Toshifumi Fujiwara, Yukio Akasaki, Hidetoshi Tsushima, Daisuke Hara, Shinkichi Arisumi, Ryosuke Tsurui, Keitaro Yasumoto, Hirokazu Saiwai, Kenichi Kawaguchi, Hisakata Yamada, Yasuharu Nakashima

{"title":"Risk factor analysis of vertebral fractures requiring surgery in patients with ankylosing spondylitis.","authors":"Kazuhiro Kai, Toshifumi Fujiwara, Yukio Akasaki, Hidetoshi Tsushima, Daisuke Hara, Shinkichi Arisumi, Ryosuke Tsurui, Keitaro Yasumoto, Hirokazu Saiwai, Kenichi Kawaguchi, Hisakata Yamada, Yasuharu Nakashima","doi":"10.1093/mr/roae048","DOIUrl":"https://doi.org/10.1093/mr/roae048","url":null,"abstract":"Objectives: This study aimed to determine the risk factors for vertebral fractures requiring surgery in patients with ankylosing spondylitis (AS).Methods: We included 60 patients with AS diagnosed by using the modified New York criteria and who were treated in our department from April 2004 to March 2019. We evaluated age, sex, disease duration, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ankylosed sacroiliac joint, bamboo spine, number of ankylosed vertebrae, and treatment (nonsteroidal antiinflammatory drugs (NSAIDs)), prednisolone (PSL), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological disease-modifying antirheumatic drugs (bDMARDs), spine surgery for vertebral fracture) at the final follow-up of the nonsurgical group and the preoperative follow-up of the surgical group.Results: At the final follow-up, the mean age was 49 years, 46 patients (75%) were male, and the mean disease duration was 27 years. Additionally, 8 (13.3%) and 43 patients (71%) underwent surgical and medical treatments, respectively. The group of surgery for vertebral fracture had significantly higher CRP levels, which was also significantly associated with vertebral fracture surgery by multivariate analysis.Conclusions: CRP was identified as a risk factor for vertebral fractures requiring surgery. Control of systemic inflammation in patients with AS may reduce the risk of vertebral fractures requiring surgery.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141097212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Golimumab in Rheumatoid Arthritis Patients at High Risk of a Poor Prognosis: Post-Hoc Analysis of GO-FORTH Study using Cluster Analysis. 戈利木单抗对预后不良风险高的类风湿关节炎患者的疗效：利用聚类分析对GO-FORTH研究进行事后分析

IF 2.2 4区医学

Modern Rheumatology Pub Date : 2024-05-23 DOI: 10.1093/mr/roae037

Teita Asano, Yutaka Ishii, Hiroaki Tsuchiya, Junya Masuda

{"title":"Efficacy of Golimumab in Rheumatoid Arthritis Patients at High Risk of a Poor Prognosis: Post-Hoc Analysis of GO-FORTH Study using Cluster Analysis.","authors":"Teita Asano, Yutaka Ishii, Hiroaki Tsuchiya, Junya Masuda","doi":"10.1093/mr/roae037","DOIUrl":"https://doi.org/10.1093/mr/roae037","url":null,"abstract":"Objectives: To assess the efficacy of golimumab (GLM) in patients with poor prognostic factors (PPFs).Methods: This is a post-hoc analysis of GO-FORTH phase 2/3 study. Cluster analysis was used to determine a patient population with high-risk patterns based on seven PPFs suggested by EULAR recommendations and limited physical function. Radiographic progression, disease activity, and physical function and associated factors were evaluated over 52 weeks.Results: Overall, 261 RA patients were classified into three clusters characterised by high disease activity, high CRP levels, and limited physical function at baseline. GLM showed suppression of progressive modified total sharp score (mTSS) and decreases in Disease Activity Score 28‒joint counts with erythrocyte sedimentation rate and Health Assessment Questionnaire‒Disease Index, in all the clusters. In cluster C that showed almost all the PPF-characteristics, a higher rate of ΔmTSS≤0 was observed in GLM 100 mg group than in GLM 50 mg group (63.9% vs 46.5%). CRP concentration and physical limitation were associated with radiographic progression of cluster C in GLM treatment.Conclusions: GLM was effective in RA patients in a subpopulation at high risk of PPF in GO-FORTH study. A dose of 100 mg may be more beneficial in preventing radiographic progression in this population. Short title: Impact of poor prognostic factors on GLM efficacy.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141081944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subtle Radiographic Progression at Six Months Can Be Detected Using Automated Quantitative Software in Rheumatoid Arthritis While Receiving Tocilizumab. 使用自动定量软件可检测类风湿关节炎患者在接受托昔单抗治疗六个月后的细微放射学进展。

IF 2.2 4区医学

Modern Rheumatology Pub Date : 2024-05-16 DOI: 10.1093/mr/roae047

Taichi Okino, Yafei Ou, Masayuki Ikebe, Akira Furusaki, Akira Sagawa, Masaru Kato, Tatsuya Atsumi, Kenneth Sutherland, Tamotsu Kamishima

{"title":"Subtle Radiographic Progression at Six Months Can Be Detected Using Automated Quantitative Software in Rheumatoid Arthritis While Receiving Tocilizumab.","authors":"Taichi Okino, Yafei Ou, Masayuki Ikebe, Akira Furusaki, Akira Sagawa, Masaru Kato, Tatsuya Atsumi, Kenneth Sutherland, Tamotsu Kamishima","doi":"10.1093/mr/roae047","DOIUrl":"https://doi.org/10.1093/mr/roae047","url":null,"abstract":"Objectives: We investigated whether our in-house software equipped with partial image phase-only correlation (PIPOC) can detect subtle radiographic joint space narrowing (JSN) progression at six months and predict JSN progression in rheumatoid arthritis (RA) patients receiving Tocilizumab.Methods: The study included 39 RA patients who were treated with Tocilizumab. Radiological progression of the metacarpophalangeal and the proximal interphalangeal joints was evaluated according to the Genant-modified Sharp score (GSS) at 0, 6, and 12 months. Automatic measurements were performed with the software. We validated the software in terms of accuracy in detecting the JSN progression.Results: The success rate of the software for joint space width (JSW) measurement was 96.8% (449/464). The 0-12-month JSW change by the software was significantly greater in joints with the 0-6-month PIPOC (+) group than the 0-6-month PIPOC (-) group (p < 0.001). The 0-12-month JSW change by the software was 0-12-month GSS (+) than with 0-12-month GSS (-) (p = 0.02). Here, \"(+)\" indicates the JSN progression during the follow-up period. Meanwhile, \"(-)\" indicates no JSN progression during the follow-up period. Linear regression tests showed significant correlations between the 0-6-month and the 0-12-month PIPOC in the left 2nd and 3rd MCP joints (R2 = 0.554 and 0.420, respectively).Conclusions: Our in-house software equipped with PIPOC could predict subsequent JSN progression with only short-term observations.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: a systematic review. 阿帕他赛治疗全身性幼年特发性关节炎的疗效和安全性：系统性综述。

IF 2.2 4区医学

Modern Rheumatology Pub Date : 2024-05-16 DOI: 10.1093/mr/roae046

Kenichi Nishimura, Takashi Ishikawa, Nami Okamoto, Keiji Akamine, Natsumi Inoue, Hitoshi Irabu, Kentaro Kato, Hiroshi Keino, Masayo Kojima, Hiroshi Kubo, Kazuichi Maruyama, Mao Mizuta, Kosuke Shabana, Masaki Shimizu, Yuko Sugita, Yukiko Takakuwa, Satoshi Takanashi, Hiroshi Takase, Hiroaki Umebayashi, Natsuka Umezawa, Shingo Yamanishi, Kazuko Yamazaki, Masato Yashiro, Takahiro Yasumi, Masaaki Mori

{"title":"Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: a systematic review.","authors":"Kenichi Nishimura, Takashi Ishikawa, Nami Okamoto, Keiji Akamine, Natsumi Inoue, Hitoshi Irabu, Kentaro Kato, Hiroshi Keino, Masayo Kojima, Hiroshi Kubo, Kazuichi Maruyama, Mao Mizuta, Kosuke Shabana, Masaki Shimizu, Yuko Sugita, Yukiko Takakuwa, Satoshi Takanashi, Hiroshi Takase, Hiroaki Umebayashi, Natsuka Umezawa, Shingo Yamanishi, Kazuko Yamazaki, Masato Yashiro, Takahiro Yasumi, Masaaki Mori","doi":"10.1093/mr/roae046","DOIUrl":"https://doi.org/10.1093/mr/roae046","url":null,"abstract":"Objectives: This systematic review assessed the efficacy and safety of abatacept in patients with systemic juvenile idiopathic arthritis (JIA).Methods: Studies published between 2000 and 2021 were searched using PubMed, Embase, Cochrane, Ichushi-Web and clinical trial registries. The risk of bias was assessed according to the manual for development clinical practice guidelines by Minds, a project to promote evidence-based medicine in Japan.Results: Seven observational studies were included. American College of Rheumatology pediatric 30/50/70 responses at 3, 6 and 12 months were 64.8%/50.3%/27.9%, 85.7%/71.4%/42.9% and 80.0%/50.0%/40.0%, respectively. Outcomes on systemic symptoms, joint symptoms and activities of daily living were not obtained. No macrophage activation syndrome or infusion reaction occurred. Serious infection occurred in 2.6% of cases.Conclusions: Abatacept improved the disease activity index. In addition, abatacept was as safe as interleukin-6 (IL -6) and IL-1 inhibitors. However, both the efficacy and safety data in this systematic review should be reviewed with caution because their quality of evidence is low or very low. Further studies are needed to confirm the efficacy and safety of abatacept for systemic JIA, especially its efficacy on joint symptoms.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors associated with drug retention of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: A multicentre REVEAL cohort study. 嗜酸性粒细胞肉芽肿伴多血管炎患者服用美泊利珠单抗后药物滞留的相关因素：REVEAL多中心队列研究。

IF 2.2 4区医学

Modern Rheumatology Pub Date : 2024-05-10 DOI: 10.1093/mr/roae044

Mayu Shiomi, Ryu Watanabe, Shogo Matsuda, Takuya Kotani, Ayana Okazaki, Yuichi Masuda, Tsuneyasu Yoshida, Mikihito Shoji, Ryosuke Tsuge, Keiichiro Kadoba, Ryosuke Hiwa, Wataru Yamamoto, Akitoshi Takeda, Yoshiaki Itoh, Motomu Hashimoto

{"title":"Factors associated with drug retention of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: A multicentre REVEAL cohort study.","authors":"Mayu Shiomi, Ryu Watanabe, Shogo Matsuda, Takuya Kotani, Ayana Okazaki, Yuichi Masuda, Tsuneyasu Yoshida, Mikihito Shoji, Ryosuke Tsuge, Keiichiro Kadoba, Ryosuke Hiwa, Wataru Yamamoto, Akitoshi Takeda, Yoshiaki Itoh, Motomu Hashimoto","doi":"10.1093/mr/roae044","DOIUrl":"https://doi.org/10.1093/mr/roae044","url":null,"abstract":"Objectives: To determine the current retention rate of mepolizumab (MPZ) and identify factors associated with drug retention in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in the Kansai multicentre cohort (REVEAL cohort).Methods: Sixty patients diagnosed with EGPA and treated with MPZ between December 2016 and June 2023 were enrolled. The clinical characteristics, including laboratory data, treatments administered, and disease course outcomes were collected retrospectively. The patients were stratified into MPZ continuation (n=53) and discontinuation (n=7) groups, and drug retention was statistically compared using the log-rank test.Results: The median age of patients was 54.5 years, with 55% females, and 33% antineutrophil cytoplasmic antibody-positive at disease onset. MPZ exhibited a retention rate of 78.7% after five years. The reasons for discontinuation included treatment of coexisting diseases, inadequate response, and remission. Patient characteristics at disease onset were comparable between the groups. Patients receiving immunosuppressants (IS) before MPZ introduction demonstrated significantly higher retention rates (P = 0.038). During the final observation, the MPZ continuation group had a lower vasculitis damage index score (P = 0.027).Conclusions: MPZ exhibited a high 5-year retention rate, particularly in patients requiring IS. This study implies that long-term use of MPZ may mitigate irreversible organ damage.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors associated with discrepancies in disease activity as assessed by SDAI and RAPID3 in patients with rheumatoid arthritis: Data from a multicenter observational study (T-FLAG). 类风湿关节炎患者通过 SDAI 和 RAPID3 评估的疾病活动性差异的相关因素：一项多中心观察研究（T-FLAG）的数据。

IF 2.2 4区医学

Modern Rheumatology Pub Date : 2024-05-10 DOI: 10.1093/mr/roae040

Mochihito Suzuki, Shuji Asai, Yoshifumi Ohashi, Yasumori Sobue, Hisato Ishikawa, Nobunori Takahashi, Kenya Terabe, Ryo Sato, Hironobu Kosugiyama, Junya Hasegawa, Yusuke Ohno, Takaya Sugiura, Shiro Imagama

{"title":"Factors associated with discrepancies in disease activity as assessed by SDAI and RAPID3 in patients with rheumatoid arthritis: Data from a multicenter observational study (T-FLAG).","authors":"Mochihito Suzuki, Shuji Asai, Yoshifumi Ohashi, Yasumori Sobue, Hisato Ishikawa, Nobunori Takahashi, Kenya Terabe, Ryo Sato, Hironobu Kosugiyama, Junya Hasegawa, Yusuke Ohno, Takaya Sugiura, Shiro Imagama","doi":"10.1093/mr/roae040","DOIUrl":"https://doi.org/10.1093/mr/roae040","url":null,"abstract":"Objectives: The present study aimed to examine discrepancies between assessments based on Routine Assessment of Patient Index Data 3 (RAPID3) and Simple Disease Activity Index (SDAI) in RA patients with controlled disease activity.Methods: Data from 464 RA patients in SDAI remission or low disease activity (REM/LDA) were analyzed. Patient-reported outcome (PRO) measures, including Health Assessment Questionnaire Disability Index (HAQ-DI), 25-question Geriatric Locomotive Function Scale (GLFS-25), and Kihon checklist (KCL), were assessed. Logistic regression models were used to identify factors associated with RAPID3 moderate or high disease activity (MDA/HDA). Cutoff values of RAPID3 MDA/HDA for each PRO evaluation item were determined using receiver operating characteristic curve analysis.Results: Among RA patients in SDAI REM/LDA, 84.9% were in RAPID3 REM/LDA. Multivariable analysis revealed that HAQ-DI, GLFS-25, and KCL were independently associated with RAPID3 MDA/HDA. Subdomain analysis of KCL revealed that activities of daily living, physical function, cognitive function, and depressive mood were significantly associated with RAPID3 MDA/HDA. Cutoff values for HAQ-DI and KCL were 0.38 and 8, respectively.Conclusions: In RA patients with controlled disease activity, discrepancies between RAPID3 and SDAI assessments were observed, with factors such as HAQ-DI, GLFS-25, and KCL being independently associated with RAPID3 MDA/HDA.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors contributing to the improvement in J-HAQ after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI). 类风湿关节炎患者在接受阿帕他赛治疗 3 年后 J-HAQ 改善的因素：日本一项长期多中心观察性研究（ORIGAMI）的中期结果。

IF 2.2 4区医学

Modern Rheumatology Pub Date : 2024-05-10 DOI: 10.1093/mr/roae043

Kenta Misaki, Eiichi Tanaka, Eisuke Inoue, Naoto Tamura, Fuminori Hirano, Yoshinori Taniguchi, Hiroshi Sato, Taio Naniwa, Hideto Oshikawa, Tamami Yoshitama, Yuya Takakubo, Yoko Suzuki, Shinkichi Himeno, Katsuki Tsuritani, Shigeru Matsumoto, Hisashi Yamanaka, Masayoshi Harigai

{"title":"Factors contributing to the improvement in J-HAQ after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI).","authors":"Kenta Misaki, Eiichi Tanaka, Eisuke Inoue, Naoto Tamura, Fuminori Hirano, Yoshinori Taniguchi, Hiroshi Sato, Taio Naniwa, Hideto Oshikawa, Tamami Yoshitama, Yuya Takakubo, Yoko Suzuki, Shinkichi Himeno, Katsuki Tsuritani, Shigeru Matsumoto, Hisashi Yamanaka, Masayoshi Harigai","doi":"10.1093/mr/roae043","DOIUrl":"https://doi.org/10.1093/mr/roae043","url":null,"abstract":"Objectives: We investigated the long-term effectiveness, safety, and factors affecting Japanese Health Assessment Questionnaire (J-HAQ) improvement during abatacept treatment in Japanese rheumatoid arthritis (RA) patients.Methods: The ORIGAMI study is an ongoing observational study of biologic-naïve RA patients with moderate disease activity treated with subcutaneous abatacept (125 mg, once-weekly). Patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) were extracted from the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) registry as an historical, weighted control group. The primary endpoint for this interim analysis was the proportion of patients with J-HAQ remission (score ≤0.5) at 3 years.Results: Among 279 abatacept-treated and 220 csDMARD-treated patients, J-HAQ remission was achieved at 3 years in 40.5% (95% confidence interval [CI] 34.7%-46.2%) and 28.9% (95% CI 9.9%-47.8%), respectively. Age, RA duration <1 year, baseline J-HAQ score, and Simplified Disease Activity Index remission at 6 months were associated with 3-year J-HAQ remission in the abatacept group. Overall, 24/298 patients (8.1%; safety analysis set) experienced serious adverse drug reactions with an incidence of 5.3 per 100 person-years.Conclusions: This study confirmed the 3-year effectiveness and safety, and revealed potential factors associated with J-HAQ remission in biologic-naïve RA patients treated with abatacept in real-world clinical practice.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LncRNA SNHG3 discriminates rheumatoid arthritis from healthy individuals and regulates inflammatory response and oxidative stress via modulating miR-128-3p. LncRNA SNHG3能区分类风湿性关节炎和健康人，并通过调节miR-128-3p调节炎症反应和氧化应激。

IF 2.2 4区医学

Modern Rheumatology Pub Date : 2024-05-06 DOI: 10.1093/mr/roae042

Kejun Li, Wei Liu, Xueru Zhao, Weiyi Lin, Wenhui Zhou

{"title":"LncRNA SNHG3 discriminates rheumatoid arthritis from healthy individuals and regulates inflammatory response and oxidative stress via modulating miR-128-3p.","authors":"Kejun Li, Wei Liu, Xueru Zhao, Weiyi Lin, Wenhui Zhou","doi":"10.1093/mr/roae042","DOIUrl":"https://doi.org/10.1093/mr/roae042","url":null,"abstract":"Objectives: This study evaluated the expression and significance of SNHG3 in Rheumatoid arthritis (RA) aiming to explore a biomarker and regulator for RA.Methods: The expression of SNHG3 in serum and synovial tissue was compared between RA patients and healthy individuals using PCR. The RA animal models were induced by the porcine type II collagen with Wistar rats and validated by the foot volume and AI score. The human fibroblast-like synoviocytes (H-FLS) were treated with LPS to mimic the injury during RA onset and the cell growth was assessed by CCK8 assay.Results: SNHG3 was significantly downregulated in the serum and synovial tissue of RA patients compared with healthy individuals. Downregulated SNHG3 could discriminate RA patients from healthy individuals with high sensitivity (0.875) and specificity (0.844). Porcine type II collagen induced increasing foot volume and AI scores of rats and SNHG3 was downregulated in RA rats. In LPS-induced H-FLS, SNHG3 negatively regulated miR-128-3p, and the alleviated effect of SNHG3 overexpression on cellular inflammation and oxidative stress was reversed by miR-128-3p upregulation.Conclusions: Serum SNHG3 was considered a potential diagnostic biomarker for RA from healthy individuals. SNHG3 regulated inflammatory response and oxidative stress via negatively modulating miR-128-3p.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0